{"id":7198,"date":"2015-01-15T04:16:45","date_gmt":"2015-01-15T04:16:45","guid":{"rendered":"http:\/\/wp.nootheme.com\/dreamer\/dummy\/?page_id=7198"},"modified":"2023-10-03T13:00:48","modified_gmt":"2023-10-03T13:00:48","slug":"nouvelles","status":"publish","type":"page","link":"https:\/\/mendelikabs.com\/fr\/nouvelles\/","title":{"rendered":"Nouvelles"},"content":{"rendered":"

[vc_row][vc_column]

[vc_column_text]Communiqu\u00e9 de presse\u00a0\u2014 le 10 f\u00e9vrier\u00a02017<\/a><\/p>\n

WEP Clinical and MendeliKABS Inc. enter exclusive Named Patient distribution agreement for MDK-Nitisinone<\/strong><\/a><\/p>\n

WEP Clinical, a global pharmaceutical and services company, and MendeliKABS Inc., a Canadian pharmaceutical company dedicated to the treatment of rare diseases, announce an exclusive Named Patient agreement to commercialise MDK-Nitisinone (nitisinone), a drug for the treatment of hereditary tyrosinemia type 1, in a number of countries where the product has no valid Marketing Authorization in place.<\/p>\n

Lire plus<\/u><\/a><\/p>\n

\n

[\/vc_column_text]

[vc_column_text]Communiqu\u00e9 de presse\u00a0\u2014 le 11 octobre 2016<\/a><\/p>\n

Sant\u00e9\u00a0Canada donne le feu vert \u00e0 MendeliKABS <\/strong>pour la commercialisation de Pr<\/sup>MDK-Nitisinone\u2122.<\/strong><\/a><\/p>\n

MendeliKABS\u00a0est fi\u00e8re d\u2019annoncer que Sant\u00e9 Canada a approuv\u00e9 le m\u00e9dicament\u00a0MDK-Nitisinone\u00a0pour le traitement de la tyrosin\u00e9mie h\u00e9r\u00e9ditaire de type\u00a01. Il s\u2019agit de la premi\u00e8re approbation par Sant\u00e9 Canada d\u2019un m\u00e9dicament pour la tyrosin\u00e9mie h\u00e9r\u00e9ditaire de type\u00a01. La Nitisinone est utilis\u00e9e pour traiter la tyrosin\u00e9mie h\u00e9r\u00e9ditaire de type\u00a01 en combinaison avec l\u2019adh\u00e9rence \u00e0 une restriction de la tyrosine dans le r\u00e9gime alimentaire. Depuis son introduction en 1991, ce traitement a remplac\u00e9 la greffe du foie en tant que traitement de premi\u00e8re ligne pour cette maladie rare.<\/p>\n

Lire plus<\/u><\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text]Communiqu\u00e9 de presse\u00a0\u2014 le 10 f\u00e9vrier\u00a02017 WEP Clinical and MendeliKABS Inc. enter exclusive Named Patient distribution agreement for MDK-Nitisinone WEP Clinical, a global pharmaceutical and services company, and MendeliKABS Inc., a Canadian pharmaceutical company dedicated to the treatment of rare diseases, announce an exclusive Named Patient agreement to commercialise MDK-Nitisinone (nitisinone), a drug for the treatment of hereditary tyrosinemia type<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7198","page","type-page","status-publish","hentry","no-featured"],"_links":{"self":[{"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/pages\/7198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/comments?post=7198"}],"version-history":[{"count":21,"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/pages\/7198\/revisions"}],"predecessor-version":[{"id":8610,"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/pages\/7198\/revisions\/8610"}],"wp:attachment":[{"href":"https:\/\/mendelikabs.com\/fr\/wp-json\/wp\/v2\/media?parent=7198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}